通过AMFR激活ER-phagy可以通过mTORC1通路减轻心脏纤维化和心肌梗塞后心肌梗塞
Zhixiang Wang1, Kaifan Niu1,2, Wei Liu1
1Department of Cardiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|July 17, 2025
概括
自克林运动因子受体 (AMFR) 通过增强ER-phagy来抑制心肌梗塞后的心肌纤维化. AMFR调节FAM134B的循环,减少纤维细胞激活,改善心脏功能.
科学领域:
- 心血管生物学 心血管生物学
- 细胞自细胞自
- 纤维化分子机制的分子机制
背景情况:
- 心肌梗塞 (MI) 后的渐进性心脏纤维化有助于病理重塑和心力衰竭.
- 细胞内网膜选择性自 (ER-phagy) 在心脏纤维化中的作用尚不清楚.
- 自克林运动因子受体 (AMFR),一个ER-phagy调节器,在心肌病理学中没有明确的功能.
研究的目的:
- 为了研究AMFR在心肌梗塞后心脏纤维化中的作用.
- 阐明AMFR影响ER-phagy和心脏纤维细胞激活的机制.
- 评估AMFR介导的ER-phagy在缓解心脏纤维化的治疗潜力.
主要方法:
- 在纤维化小鼠心脏组织和TGF-β1刺激心脏纤维细胞中分析ER-phagy活性.
- 评估心脏功能和纤维化在AMFR淘汰赛小鼠后MI.
- 单细胞RNA测序 (scRNA-seq) 的心脏纤维细胞.
- 调查AMFR对益菌原蛋白表达和ER-phagy流量的影响.
- 对mTORC1信号通路的组件进行ubiquitination测定和分析.
主要成果:
- 在心脏病发作后的纤维性心脏中,FAM134B介导的ER-phagy活性升高,以及对TGF-β1.1的反应.
- AMFR敲击加剧心脏纤维化和心脏功能恶化后MI.
- 无AMFR的心脏纤维细胞表现出肌纤维细胞表型,而AMFR过度表达抑制了益菌原性标记物.
- 发现AMFR可以调节ER-phagy流量和FAM134B周转率,抑制心脏纤维细胞激活.
- AMFR催化了FAM134B的泛化,增强了ER-phagy并抑制了mTORC1的信号传递.
结论:
- 通过增强ER-phagy,AMFR对心脏纤维化后心脏病发作起着保护作用.
- 由AMFR介导的ER-phagy抑制心脏纤维细胞激活和肌纤维细胞分化.
- 对于心力衰竭治疗,AMFR对FAM134B无化和ER-phagy流量的调节提供了一个潜在的治疗标.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
cAMP-dependent Protein Kinase Pathways
6.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K


